NATIONAL COMPREHENSIVE CANCER NETWORK IMAGE: JNCCN COVER, OCTOBER 2022 CREDIT: NCCN PLYMOUTH MEETING, PA [October 17, 2022] — New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment. The researchers analyzed the frequency of side effects...
by Lancet Credit: Pixabay/CC0 Public Domain A review of adverse events following vaccination against COVID-19 with mRNA vaccines in the U.S. confirms that most side effects were mild and decreased substantially after one day. The new study, published in The Lancet Infectious Diseases journal, suggests that for more than 298 million vaccine doses administered between December 2020...
by Massachusetts General Hospital Credit: Pixabay/CC0 Public Domain An additional “booster” dose of Moderna or Pfizer mRNA-based vaccine is needed to provide immunity against the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, according to a study by researchers at the Ragon Institute of MGH, MIT, and Harvard. The results of this study, reported...
by The Francis Crick Institute Credit: Unsplash/CC0 Public Domain Patients receiving in-hospital dialysis treatment for kidney disease produce a larger neutralizing antibody response when given the Pfizer-BioNTech COVID-19 vaccine, compared to the Oxford-AstraZeneca vaccine, according to laboratory findings published today (Thursday) as a Correspondence in The Lancet. It is reported that immunocompromised patients will be prioritized to...
By Dr. Sanchari Sinha Dutta, Ph.D. Aug 2 2021 Scientists in the Netherlands recently conducted an open-level, randomized-controlled trial to evaluate the safety and immunogenicity of fractional intradermal doses of the mRNA-based coronavirus disease 2019 (COVID-19) vaccine mRNA-1273 (Moderna). The trial findings reveal that the fractional dose regimen of the Moderna vaccine is well tolerated...
